2025-10-09 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX) based on the data you provided, formatted as requested.

**Report on TG Therapeutics Inc. (TGTX)**

**Company Overview:**

TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**1. Performance vs. S&P 500 (VOO) and Alpha/Beta Analysis**

*   **Cumulative Return Difference:** TGTX's cumulative return is 88.61% compared to VOO's 99.62%, resulting in a difference of -4.90%.
*   **Relative Deviation:**  The relative deviation is 23.6, indicating that TGTX's performance is currently positioned in the lower end of its historical performance range compared to VOO.

**Alpha/Beta Analysis Table:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2015-2017  | -5.0%   | 73.5% | -33.0%  | -0.0   | 1.3    |
| 2016-2018  | -12.0%  | 73.5% | -27.0%  | -0.0   | 0.7    |
| 2017-2019  | 74.0%   | 74.1% | 52.0%   | 0.0    | 1.8    |
| 2018-2020  | 316.0%  | 74.1% | 293.0%  | 0.1    | 8.2    |
| 2019-2021  | 124.0%  | 74.1% | 78.0%   | 0.3    | 3.0    |
| 2020-2022  | -71.0%  | 77.8% | -71.0%  | -0.0   | 1.9    |
| 2021-2023  | -284.0% | 77.8% | -285.0% | -1.1   | 2.7    |
| 2022-2024  | 56.0%   | 77.8% | 36.0%   | -1.0   | 4.8    |
| 2023-2025  | 89.0%   | 74.8% | 25.0%   | -0.1   | 5.7    |

*   **Analysis:**  The table shows a highly volatile history. High MDD (Maximum Drawdown) values indicate significant potential losses. Alpha values fluctuate widely, suggesting periods of both outperformance and underperformance compared to the market.  Beta values are generally low.

**2. Recent Price Action**

*   **Current Price:** \$35.75
*   **Recent Change:**  The price decreased by \$2.05 from the previous close.
*   **Moving Averages:**
    *   5-day MA: \$36.48
    *   20-day MA: \$34.65
    *   60-day MA: \$32.65

*   **Analysis:** The stock price is currently below its 5-day moving average but above its 20-day and 60-day moving averages. This suggests a possible short-term downward trend, but the price remains above longer-term averages. The recent decrease indicates some selling pressure.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 69.15 (Approaching overbought territory)
*   **PPO:** 0.08 (Positive, indicating upward momentum)
*   **Hybrid Signal:** `cash_0%_Buy 100% of cash` (Strong buy signal with low cash holding)
*   **Delta Previous Relative Divergence:** 1.0 (+):  Indicates short-term upward momentum.
*   **Expected Return:** -93.3% (Significant underperformance expected relative to the S&P 500 over the long term if holding this stock)
*   **Analysis:** The MRI suggests a favorable investment environment, despite the extremely low expected return relative to the S&P 500. However, the high RSI signals it is approaching overbought, and a negative expected return relative to the market.

**4. Recent News & Significant Events**

*   **[2025-10-08]** Argus Research Analysis
*   **[2025-10-04]** Institutional Investor Activity (Positive Market Cap Gain)
*   **[2025-10-04]** Briumvi Safety Data (6-Year Results)
*   **[2025-09-24]** Briumvi Data: High Percentage of MS Patients Free From Progression
*   **[2025-09-24]** Briumvi Data: Disability Progression Results

*   **Analysis:** Recent news is heavily focused on positive data regarding Briumvi, a key drug for TG Therapeutics. Institutional investor activity and analyst coverage (Argus) suggest growing confidence in the company's prospects.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean Rating: 1.78)
*   **Target Price:** Avg: \$43.57, High: \$60.00, Low: \$11.00
*   **Recent Rating Changes:** Not Available (No changes provided)

*   **Analysis:**  Analysts generally have a positive outlook, with a "Buy" consensus and a significant upside potential based on the average target price. However, the wide range between the high and low target prices suggests considerable uncertainty.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-08-08 | 0.19 | \$0.14B     |
| 2025-05-09 | 0.03 | \$0.12B     |
| 2024-11-07 | 0.03 | \$0.08B     |
| 2024-08-09 | 0.05 | \$0.07B     |
| 2025-08-08 | 0.05 | \$0.07B     |

*   **Analysis:** The most recent quarter (2025-08-08) shows a significant jump in EPS and Revenue. This is a very positive sign of increasing profitability and revenue growth.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | \$0.14B   | 86.58%        |
| 2025-03-31 | \$0.12B   | 87.14%        |
| 2024-12-31 | \$0.11B   | 85.77%        |
| 2024-09-30 | \$0.08B   | 88.86%        |
| 2024-06-30 | \$0.07B   | 88.70%        |

**Capital and Profitability**

| Quarter    | Equity    | ROE    |
|------------|-----------|--------|
| 2025-06-30 | \$0.28B   | 10.20% |
| 2025-03-31 | \$0.24B   | 2.13%  |
| 2024-12-31 | \$0.22B   | 10.49% |
| 2024-09-30 | \$0.19B   | 2.02%  |
| 2024-06-30 | \$0.18B   | 3.87%  |

*   **Analysis:**
    *   Revenue is consistently growing over the past several quarters.
    *   Profit margins are exceptionally high and relatively stable.
    *   Equity is increasing, reflecting growth in the company's net assets.
    *   ROE fluctuates, with peaks in 2024-12-31 and 2025-06-30, indicating varying levels of profitability relative to equity.

**7. Overall Summary**

TG Therapeutics (TGTX) presents a mixed picture. Recent clinical trial data for Briumvi are promising, and analysts have a generally positive outlook. The company's revenue and profit margins are strong and growing. However, the stock has a volatile history and has underperformed the S&P 500 recently. The technical indicators show conflicting signals, with the RSI approaching overbought and a low expected return relative to the S&P 500.

*   **Positive Factors:** Strong revenue and profit margin growth, positive Briumvi data, and a buy consensus from analysts.
*   **Negative Factors:** Volatile historical performance, recent underperformance vs. S\&P 500, negative expected return, and potentially overbought RSI.

**Disclaimer:** This analysis is based solely on the provided data and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
